Preclinical AML studies showed palbociclib plus venetoclax produced stronger, more durable anti‑leukemia activity than venetoclax alone and may overcome resistance.

“We are encouraged by the emerging data from our lung cancer programs, where systemically delivered Olvi-Vec continues to ...

A research team at Oregon Health & Science University has discovered a promising new drug combination that may help people ...

The review emphasizes how breakthroughs in understanding the molecular mechanisms of cell cycle regulation have paved the way for the development of targeted anti-cancer agents. Notably, inhibitors of ...

Lung cancer patients receiving immunochemotherapy earlier in the day had a 52% lower risk of progression in a new medical ...

In 2016, Colinda Scheele, a cancer biologist at Catholic University Leuven, was studying how chemotherapy affects breast cancer cells in mice. However, she observed an inconsistency: Some cell ...

Tarlatamab, a bispecific T-cell engager immunotherapy targeting delta-like ligand 3 and CD3, showed promising antitumor activity in a phase 1 trial in patients with previously treated small-cell lung ...

Therapeutic cancer vaccines have experienced a remarkable resurgence over the past decade, representing a paradigm shift in oncology toward harnessing the immune system's intrinsic ability to combat ...

Rb1 loss may serve as a predictive biomarker to guide new targeted therapies for select breast cancers resistant to standard ...

A pair of well-known marijuana compounds work in tandem to target ovarian cancer cells In A Nutshell CBD and THC killed ovarian cancer cells at low doses while normal cells required 4-5 times higher ...